The first ever treatment for dry AMD

OpRegen, developed by Israel’s CellCure NeuroSciences is designed to treat patients with the severe stage of the dry form of age-related macular degeneration (dry-AMD).  Dry-AMD is the leading cause of visual impairment in an aging population.  No approved therapy currently exists.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *